Home
EN / FR

Celyad Oncology

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

376_981be_rev-1

Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

October 1, 2021
READ THE PRESS RELEASE

Celyad Oncology announces September 2021 Conference Schedule

September 1, 2021
READ THE PRESS RELEASE

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

August 4, 2021
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

July 30, 2021
READ THE PRESS RELEASE

Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

July 29, 2021
READ THE PRESS RELEASE

Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day

July 20, 2021
READ THE PRESS RELEASE

Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

July 13, 2021
READ THE PRESS RELEASE

Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

July 7, 2021
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

June 30, 2021
READ THE PRESS RELEASE

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

June 11, 2021
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology@CelyadSA·
7h

Our first armored #CART candidate is engineered to co-express the cytokine IL-18 with the NKG2D CAR . Submission of the IND application for the treatment of #solidtumors is expected in mid-2022. Learn more here: https://buff.ly/3jyIa6V

Celyad Oncology@CelyadSA·
21 Oct

This Saturday, October 23, our CEO Filippo Petti will discuss our company, technologies, and #celltherapy candidates for cancer at the VFB Happening Event in Antwerpen, Belgium. Click here for more info and to register: https://buff.ly/3n4RY9F

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you accept that your data will be sent to us and processed by our provider in order to send you our newsletter. You can find more information on how we process your data in our Privacy Policy.